Alterity Therapeutics (ATHE) Other Non-Current Assets (2015 - 2016)
Alterity Therapeutics' quarterly Other Non-Current Assets came in at $32998.0 in Q4 2016, up 0.85% year-on-year from $32718.6 in Q1 2016, and little changed quarter-over-quarter from $32845.9 in Q2 2016.
Alterity Therapeutics has reported Other Non-Current Assets for 2 years, with the latest figure at $32998.0 in Q4 2016.
- For the quarter ending Q4 2016, Other Non-Current Assets rose 0.85% year-over-year to $32998.0; the trailing twelve-month figure through Dec 2016 stood at $32998.0 (up 0.85% YoY), and the FY2016 full-year result was $32998.0, changed N/A from the prior year.
- Other Non-Current Assets for Q4 2016 stood at $32998.0, roughly flat from $32845.9 in the prior quarter.
- The five-year high for Other Non-Current Assets was $35343.2 in Q2 2015, with the low at $32718.6 in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 4.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 32,997.97 |
| Jun 30, 2016 | 32,845.95 |
| Dec 31, 2015 | 32,718.55 |
| Jun 30, 2015 | 35,343.19 |